Femasys Inc (FEMY) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Femasys Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Femasys Inc's ROI in the second quarter of 2026?
Femasys Inc recorded a cumulative net loss of $-12 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -108.92%.
Within the Healthcare sector 625 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3686 to 4104.
Femasys Expands European Footprint with Strategic Distribution Partnerships, Despite Financial ChallengesFemasys Inc. a notable player in the healthcare technology sector, has recently secured strategic distribution partnerships to further the commercialization of its innovative women s reproductive healthcare product, FemaSeed, in the Spanish market. This development comes at a crucial juncture for the company, which recently recorded a cumulative net loss of $17 million for the twelve months ending in the second quarter of 2024, revealing a troubling negative return on investment (ROI) of -93.73%.The partnerships with Comercial Medico Quirurgica, SA and Durgalab, the company’s inaugural distributors in the European Union, mark a significant step in Femasys s efforts to enhance its market presence. Both companies are poised to catalyze the penetration of FemaSeed a CE-marked medical device designed to support women s reproductive health into new territories, generating potential revenue streams that could alleviate the financial pressures currently facing Femasys.
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check In a significant advancement for women s health, Femasys Inc. a pioneering force in female healthcare solutions, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for FemChec. This groundbreaking contrast-generating product is designed to facilitate the evaluation of fallopian tube patency, a critical aspect of diagnostics in women s reproductive health.FemChec is an essential component in the diagnostic confirmation test that follows the administration of FemBloc, Femasys non-surgical, permanent birth control solution. Currently in an advanced stage of its pivotal trial, FemBloc stands poised to offer a non-invasive alternative to surgical sterilization procedures, further underscoring the innovative strides made by Femasys in this domain.
Femasys CEO Meets with White House Gender Policy Council to Discuss Revolutionary Women s Reproductive Health Products, Impacting Share Price Negatively in Q2 2024 In a groundbreaking development, Kathy Lee-Sepsick, the CEO and Founder of Femasys, recently had the honor of meeting with the White House Gender Policy Council to discuss the Atlanta-based biomedical company s remarkable advancements in women s reproductive health products. The significance of this meeting cannot be overstated, as it reflects the growing recognition of the crucial role played by Femasys in empowering women with safe and effective healthcare solutions. During the highly anticipated meeting, Lee-Sepsick passionately conveyed Femasys commitment to developing cutting-edge technologies aimed at addressing the unique challenges faced by women in the realm of reproductive health. Armed with a deep understanding of both the medical and societal implications, she elaborated on the company s unwavering dedication to breaking down barriers and improving access to essential healthcare services for women across the nation.
Femasys Inc, a leading healthcare company, recently announced the addition of experienced professionals to its commercial management team. The new hires are expected to drive strategic initiatives and launch efforts at the upcoming 2024 ACOG (American College of Obstetricians and Gynecologists) Meeting. This move comes as Femasys aims to further strengthen its position in the market and expand its product offerings. Over the past 90 days, Femasys share price has demonstrated an impressive growth of 66.04%. This spike in share value indicates the positive market sentiment surrounding the company s recent developments. Femasys expansion plans, coupled with a strong strategic approach by the management team, have indeed resonated with investors.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
